Katherine L. Morel

Bedford Park
Adelaide, SA, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer.

EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer.

Journal: Research square

Published: September 02, 2025

EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer.

EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer.

Journal: bioRxiv : the preprint server for biology

Published: August 20, 2025

MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer.

MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer.

Journal: bioRxiv : the preprint server for biology

Published: February 14, 2024

MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer.

MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer.

Journal: Cancer research communications

Published: February 03, 2024

Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.

Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.

Journal: The Journal of clinical investigation

Published: September 29, 2023

EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.

EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.

Journal: Nature cancer

Published: April 26, 2021

NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.

NF-κB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants.

Journal: Molecular cancer research : MCR

Published: February 06, 2021

Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer.

Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer.

Journal: Cancer prevention research (Philadelphia, Pa.)

Published: April 19, 2020

The Role of RB in Prostate Cancer Progression.

The Role of RB in Prostate Cancer Progression.

Journal: Advances in experimental medicine and biology

Published: January 05, 2020

Targeting RET Kinase in Neuroendocrine Prostate Cancer.

Targeting RET Kinase in Neuroendocrine Prostate Cancer.

Journal: Molecular cancer research : MCR

Published: December 23, 2019

DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues In Vivo.

DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues In Vivo.

Journal: Radiation research

Published: May 17, 2019

The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth In Vivo than Either Drug Alone.

The Combination of Metformin and Valproic Acid Has a Greater Anti-tumoral Effect on Prostate Cancer Growth In Vivo than Either Drug Alone.

Journal: In vivo (Athens, Greece)

Published: October 16, 2018

Showing 1-12 of 17

Last Updated: 09/26/2026